Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients

NCT05625529 is registered in ClinicalTrials.gov with Biological Dynamics as lead sponsor.

NCT NCT05625529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05625529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients
Lead sponsor
Biological Dynamics
Phase
Observational
Overall status
Recruiting
Start date
December 19, 2022
Completion date
January 1, 2028
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

exosomes, extracellular vesicles, pancreas cancer, pancreatic neoplasms